| Chestnut Hill Of East Longmeadow | |
| 32 Chestnut Street, East Longmeadow, Massachusetts 01028 | |
| (413) 525-1893 | |
| Name | Chestnut Hill Of East Longmeadow |
|---|---|
| Location | 32 Chestnut Street, East Longmeadow, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 135 |
| Occupancy Rate | 60.37% |
| Medicare ID (CCN) | 225303 |
| Legal Business Name | Bear Mt East Longmeadow Llc |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1467912105 |
| Organization Name | BEAR MT EAST LONGMEADOW LLC |
| Address | 32 Chestnut St, East Longmeadow, MA 01028 |
| Phone Number | 413-525-1893 |
News Archive
Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.
Babies born prematurely to low-income parents have a disproportionately high risk for developing dangerous brain bleeds that require multiple surgeries and extensive follow-up, according to a small Johns Hopkins Children's Center study.
A world-first QUT study revealing light exposure plays a role in the weight of preschool children has been published by international research journal PLOS ONE.
Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.
Biotech company Pharming Group NV ("Pharming" or "the Company") today received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin.
› Verified 6 days ago
| NPI Number | 1750331286 |
| Organization Name | SRC EAST LONGMEADOW, INC. |
| Doing Business As | WINGATE AT EAST LONGMEADOW REHAB. & SKILLED NSG. RESIDENCE |
| Address | 32 Chestnut St, East Longmeadow, MA 01028 |
| Phone Number | 413-525-1893 |
News Archive
Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.
Babies born prematurely to low-income parents have a disproportionately high risk for developing dangerous brain bleeds that require multiple surgeries and extensive follow-up, according to a small Johns Hopkins Children's Center study.
A world-first QUT study revealing light exposure plays a role in the weight of preschool children has been published by international research journal PLOS ONE.
Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.
Biotech company Pharming Group NV ("Pharming" or "the Company") today received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin.
› Verified 6 days ago
| NPI Number | 1972593523 |
| Organization Name | CHESTNUT HILL REHABILITATION AND NURSING CENTER |
| Doing Business As | RADIUS 91 OPERATING CHESTNUT HILL |
| Address | 32 Chestnut St, East Longmeadow, MA 01028 |
| Phone Number | 413-525-1893 |
News Archive
Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.
Babies born prematurely to low-income parents have a disproportionately high risk for developing dangerous brain bleeds that require multiple surgeries and extensive follow-up, according to a small Johns Hopkins Children's Center study.
A world-first QUT study revealing light exposure plays a role in the weight of preschool children has been published by international research journal PLOS ONE.
Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.
Biotech company Pharming Group NV ("Pharming" or "the Company") today received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.
Babies born prematurely to low-income parents have a disproportionately high risk for developing dangerous brain bleeds that require multiple surgeries and extensive follow-up, according to a small Johns Hopkins Children's Center study.
A world-first QUT study revealing light exposure plays a role in the weight of preschool children has been published by international research journal PLOS ONE.
Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.
Biotech company Pharming Group NV ("Pharming" or "the Company") today received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.19 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.84 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 70.15 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.27 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.45 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.33 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.63 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.42 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.6 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 89.01 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.69 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 23.97 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.85 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.4 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.66 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 57.67 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 93.81 | 82.93 |
News Archive
Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.
Babies born prematurely to low-income parents have a disproportionately high risk for developing dangerous brain bleeds that require multiple surgeries and extensive follow-up, according to a small Johns Hopkins Children's Center study.
A world-first QUT study revealing light exposure plays a role in the weight of preschool children has been published by international research journal PLOS ONE.
Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.
Biotech company Pharming Group NV ("Pharming" or "the Company") today received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin.
› Verified 6 days ago
Care One At Redstone Location: 135 Benton Drive, East Longmeadow, Massachusetts 01028 Phone: (413) 525-3336 | |
Chestnut Hill Of East Longmeadow Location: 32 Chestnut Street, East Longmeadow, Massachusetts 01028 Phone: (413) 525-1893 | |
East Longmeadow Skilled Nursing Center Location: 305 Maple Street, East Longmeadow, Massachusetts 01028 Phone: (413) 525-6361 |